{"id":"placebo-priming","safety":{"commonSideEffects":[{"rate":null,"effect":"Disappointment or loss of efficacy upon disclosure of placebo status"},{"rate":null,"effect":"Ethical concerns regarding informed consent"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Placebo priming involves pre-treating or priming patients with placebo interventions to activate endogenous healing pathways, including neurobiological reward systems and immune modulation. This approach capitalizes on the placebo effect—the therapeutic benefit derived from expectation and context—to potentiate subsequent treatment efficacy or standalone symptom improvement. The mechanism relies on classical conditioning, expectancy-driven neurochemical changes, and the patient's belief in treatment effectiveness.","oneSentence":"Placebo priming leverages expectancy and conditioning effects to enhance the body's natural healing response through psychological and physiological mechanisms.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T00:01:29.346Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Chronic pain conditions"},{"name":"Depression and anxiety disorders"},{"name":"Irritable bowel syndrome"},{"name":"Parkinson's disease motor symptoms"}]},"trialDetails":[{"nctId":"NCT05029141","phase":"PHASE2","title":"New Double Epigenetic Regimen in the Treatment of Relapsed or Refractory Acute Myeloid Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"The First Affiliated Hospital of Soochow University","startDate":"2021-09-01","conditions":"Acute Myeloid Leukemia, Refractory Acute Leukemia, Relapsed Adult AML","enrollment":21},{"nctId":"NCT05634876","phase":"PHASE1","title":"UB-312 in Patients With Synucleinopathies","status":"COMPLETED","sponsor":"NYU Langone Health","startDate":"2023-05-31","conditions":"Multiple System Atrophy, Parkinson Disease","enrollment":8},{"nctId":"NCT06842745","phase":"PHASE2","title":"Transcranial Magnetic Stimulation + Language Therapy to Treat Mild Aphasia","status":"RECRUITING","sponsor":"University of Pennsylvania","startDate":"2025-02-11","conditions":"Aphasia, Stroke, Aphasia Following Cerebral Infarction","enrollment":24},{"nctId":"NCT03866187","phase":"PHASE1, PHASE2","title":"Safety, Efficacy, Immunogenicity Study of GSK Biologicals' HBV Viral Vector and Adjuvanted Proteins Vaccine (GSK3528869A) in Adult Patients With Chronic Hepatitis B Infection","status":"TERMINATED","sponsor":"GlaxoSmithKline","startDate":"2019-03-28","conditions":"Hepatitis B, Chronic","enrollment":236},{"nctId":"NCT07399132","phase":"EARLY_PHASE1","title":"A Study of APL-10456-Vaccine","status":"RECRUITING","sponsor":"Apollo Therapeutics Ltd","startDate":"2026-02-16","conditions":"Rhinovirus","enrollment":144},{"nctId":"NCT07404085","phase":"NA","title":"Epigenetic Enhancement of Cognitive Training in Aging Mood Disorder Populations","status":"RECRUITING","sponsor":"Mental Health Centre Copenhagen, Bispebjerg and Frederiksberg Hospital","startDate":"2025-11-14","conditions":"Bipolar Disorder (BD), Depression - Major Depressive Disorder, Cognitive Impairment","enrollment":160},{"nctId":"NCT04616781","phase":"PHASE2, PHASE3","title":"Ketone Ester Intervention in Alcohol Use Disorder","status":"RECRUITING","sponsor":"University of Pennsylvania","startDate":"2021-04-05","conditions":"Alcohol Drinking, Alcohol Use Disorder","enrollment":20},{"nctId":"NCT07398300","phase":"NA","title":"Insulin-Mediated Glucose Uptake and Organ Perfusion Assessed by Total-Body PET During GIP and GLP-1 Infusion","status":"RECRUITING","sponsor":"Rigshospitalet, Denmark","startDate":"2026-03-12","conditions":"Type 2 Diabetes, Healhty","enrollment":36},{"nctId":"NCT07394426","phase":"EARLY_PHASE1","title":"A Phase I Study of PepGNP-ChikV in Healthy Volunteers","status":"NOT_YET_RECRUITING","sponsor":"Gylden Pharma Ltd","startDate":"2026-08-03","conditions":"Chikungunya, Chikungunya Fever, Chikungunya Virus Infection","enrollment":40},{"nctId":"NCT07356687","phase":"NA","title":"Effects of rTMS Combined With Dual-Task Gait Training on Walking and Cognition After Stroke","status":"RECRUITING","sponsor":"The Hong Kong Polytechnic University","startDate":"2026-01-21","conditions":"Stroke","enrollment":184},{"nctId":"NCT03040999","phase":"PHASE3","title":"Study of Pembrolizumab (MK-3475) or Placebo With Chemoradiation in Participants With Locally Advanced Head and Neck Squamous Cell Carcinoma (MK-3475-412/KEYNOTE-412)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2017-04-05","conditions":"Head and Neck Neoplasms","enrollment":804},{"nctId":"NCT05471076","phase":"PHASE1","title":"Trial to Evaluate the Safety and Immunogenicity of Priming Regimens of 426c.Mod.Core-C4b and Optional Boost Regimen With HIV Trimer BG505 SOSIP.GT1.1 gp140, Both Adjuvanted With 3M-052-AF + Alum in Healthy, Adult Participants Without HIV","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2022-08-22","conditions":"HIV-1-infection","enrollment":52},{"nctId":"NCT07347340","phase":"PHASE3","title":"Testing Herbal Pretreatment For IVF Success In Women With Low Ovarian Reserve","status":"NOT_YET_RECRUITING","sponsor":"Peking Union Medical College Hospital","startDate":"2026-01-01","conditions":"Diminished Ovarian Reserve (DOR)","enrollment":348},{"nctId":"NCT06128733","phase":"PHASE1, PHASE2","title":"Study of an Investigational Pentavalent Meningococcal ABCYW Vaccine in Adults and Adolescents","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2023-10-31","conditions":"Meningococcal Immunisation, Healthy Volunteers","enrollment":1215},{"nctId":"NCT05898022","phase":"PHASE4","title":"Pragmatic Research on Diuretic Management in Early BPD Pilot","status":"COMPLETED","sponsor":"Children's Hospital Medical Center, Cincinnati","startDate":"2023-08-17","conditions":"Bronchopulmonary Dysplasia","enrollment":19},{"nctId":"NCT05361733","phase":"PHASE1","title":"A First in Human Study of the Safety, Tolerability, and the Physiologically Based Pharmacokinetics of XFB19 in Healthy Adult Volunteers.","status":"NOT_YET_RECRUITING","sponsor":"Xfibra, Inc.","startDate":"2026-01-15","conditions":"Focus of the Study: Safety of XFB19","enrollment":40},{"nctId":"NCT07271056","phase":"NA","title":"Sublingual Misoprostol Versus No Cervical Priming Before Hysteroscopic Resection of Symptomatic Uterine Niches","status":"COMPLETED","sponsor":"Benha University","startDate":"2025-02-11","conditions":"Scar Niche, Abnormal Uterine Bleeding, Cesarean Section Complications","enrollment":56},{"nctId":"NCT06881888","phase":"PHASE1","title":"Intranasal Delivery of Octreotide for Treatment of Diabetic Macular Edema","status":"NOT_YET_RECRUITING","sponsor":"University of Alabama at Birmingham","startDate":"2026-08-31","conditions":"Diabetic Macular Edema","enrollment":60},{"nctId":"NCT07197346","phase":"NA","title":"Repetitive Transcranial Magnetic Stimulation Primed Self-controlled Practice on Motor Learning","status":"RECRUITING","sponsor":"National Taiwan University Hospital","startDate":"2025-09-01","conditions":"rTMS Stimulation, Autonomy, Healthy Young Adults","enrollment":72},{"nctId":"NCT06055361","phase":"PHASE1","title":"A Study to Investigate the Safety, Tolerability, and Efficacy of BxC-I17e Single and Multiple Dose SC Injection in Patients With Moderate to Severe Atopic Dermatitis","status":"RECRUITING","sponsor":"Brexogen Inc.","startDate":"2023-04-18","conditions":"Atopic Dermatitis","enrollment":45},{"nctId":"NCT04183335","phase":"PHASE3","title":"Study of Dupilumab for the Treatment of Patients With Prurigo Nodularis, Inadequately Controlled on Topical Prescription Therapies or When Those Therapies Are Not Advisable (LIBERTY-PN PRIME)","status":"COMPLETED","sponsor":"Sanofi","startDate":"2019-12-12","conditions":"Neurodermatitis","enrollment":151},{"nctId":"NCT07108621","phase":"PHASE3","title":"hCG Priming in Women With Diminished Ovarian Reserve","status":"RECRUITING","sponsor":"Kristine Loessl","startDate":"2025-09","conditions":"Infertility, Female, Ovarian Reserve, In Vitro Fertilization (IVF)","enrollment":80},{"nctId":"NCT00696033","phase":"NA","title":"Exploring the Effects of Diazepam and Lorazepam","status":"COMPLETED","sponsor":"University Hospital, Strasbourg, France","startDate":"2007-07","conditions":"Healthy Subjects","enrollment":22},{"nctId":"NCT04607850","phase":"PHASE1, PHASE2","title":"Prime-boost Vaccine Study in Women With Low-grade Cervical HPV Lesions","status":"COMPLETED","sponsor":"Barinthus Biotherapeutics","startDate":"2021-03-16","conditions":"HPV Infection, CIN1","enrollment":108},{"nctId":"NCT05604209","phase":"PHASE1","title":"Safety and Immunogenicity of HIV-1 Vaccines C62-M4 or C1C62-M3M4 in Persons With HIV-1 Suppressed on ART","status":"COMPLETED","sponsor":"University of North Carolina, Chapel Hill","startDate":"2022-10-13","conditions":"HIV Vaccine, HIV-1-infection","enrollment":18},{"nctId":"NCT05355337","phase":"PHASE3","title":"Pramipexole for Anhedonic Depression","status":"ACTIVE_NOT_RECRUITING","sponsor":"Region Skane","startDate":"2023-02-08","conditions":"Psychiatric Disorders Mood, Anhedonia, Depression","enrollment":120},{"nctId":"NCT07058324","phase":"NA","title":"The Effects of Chicory Root-derived Prebiotic on Mood and Stress Responsiveness in Healthy Adults With Mild to Moderate Levels of Stress and Anxiety","status":"RECRUITING","sponsor":"Beneo-Institute","startDate":"2025-06-02","conditions":"Stress, Healthy Subjects, Anxiety, Mild to Moderate","enrollment":204},{"nctId":"NCT02952833","phase":"PHASE1","title":"ZIKA Vaccine in Naive Subjects","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2016-10-14","conditions":"Zika Virus Infection","enrollment":91},{"nctId":"NCT06799260","phase":"NA","title":"Motor Cortex Plasticity Response to Theta-Burst Stimulation After Ketone Monoester Supplementation","status":"ACTIVE_NOT_RECRUITING","sponsor":"Universiti Putra Malaysia","startDate":"2024-12-18","conditions":"Healthy Young Adult, Neurophysiology","enrollment":40},{"nctId":"NCT02543268","phase":"PHASE3","title":"A Study to Evaluate the Immunogenicity, Safety and Tolerability of Ad26.ZEBOV and MVA-BN-Filo in Healthy Adult Participants","status":"COMPLETED","sponsor":"Crucell Holland BV","startDate":"2015-09-21","conditions":"Healthy","enrollment":329},{"nctId":"NCT04715022","phase":"PHASE1, PHASE2","title":"Sympathetic-vascular Dysfunction in Obesity and Insulin Resistance (Vitamin C Study)","status":"RECRUITING","sponsor":"University of Kansas Medical Center","startDate":"2021-06-17","conditions":"Hypertension, Cardiovascular Diseases","enrollment":23},{"nctId":"NCT06221813","phase":"PHASE1","title":"Study to Evaluate Safety and Immunogenicity of a Prime-Boost Regimen of rVSV-Nipah Virus Vaccine Candidate PHV02 in Healthy Adult Subjects","status":"COMPLETED","sponsor":"Public Health Vaccines LLC","startDate":"2024-01-26","conditions":"Nipah Virus Infection","enrollment":120},{"nctId":"NCT04832009","phase":"EARLY_PHASE1","title":"Reversing Glucose and Lipid-mediated Vascular Dysfunction","status":"RECRUITING","sponsor":"University of Kansas Medical Center","startDate":"2022-05-09","conditions":"Blood Pressure, Hypertension","enrollment":46},{"nctId":"NCT02935686","phase":"PHASE1, PHASE2","title":"A Safety, Tolerability and Immunogenicity Study of 2 Different Regimens of Tetravalent Ad26.Mos4.HIV Prime Followed by Boost With Tetravalent Ad26.Mos4.HIV Along With Either Clade C gp140 Plus Adjuvant OR With a Combination of Mosaic and Clade C gp140 Plus Adjuvant in Healthy HIV Uninfected Adults","status":"COMPLETED","sponsor":"Janssen Vaccines & Prevention B.V.","startDate":"2017-03-31","conditions":"Healthy","enrollment":155},{"nctId":"NCT02788045","phase":"PHASE1, PHASE2","title":"Safety, Tolerability and Immunogenicity Study of Different Vaccine Regimens of Trivalent Ad26.Mos.HIV or Tetravalent Ad26.Mos4.HIV Along With Clade C Glycoprotein (gp)140 in Healthy Human Immunodeficiency Virus (HIV)-Uninfected Adults","status":"COMPLETED","sponsor":"Janssen Vaccines & Prevention B.V.","startDate":"2016-07-08","conditions":"Healthy","enrollment":201},{"nctId":"NCT02543567","phase":"PHASE3","title":"A Study to Evaluate A Range of Dose Levels of Ad26.ZEBOV and MVA-BN-Filo in Healthy Adult Participants","status":"COMPLETED","sponsor":"Janssen Vaccines & Prevention B.V.","startDate":"2015-09-21","conditions":"Healthy","enrollment":525},{"nctId":"NCT06541093","phase":"EARLY_PHASE1","title":"Study to Evaluate the Safety and Immunogenicity of an HIV-1 Vaccine Regimen of Adjuvanted UVAX-1107 Followed by Adjuvanted UVAX-1107 or Adjuvanted UVAX-1197 in Healthy Subjects Aged 25-55 Years.","status":"COMPLETED","sponsor":"Uvax Bio LLC","startDate":"2024-01-30","conditions":"AIDS/HIV - RelatedDisease Associated With AIDS, Vaccine-Preventable Diseases, HIV Infections","enrollment":34},{"nctId":"NCT04668339","phase":"PHASE2","title":"A Trial Evaluating the Safety and Effects of an RNA Vaccine ARCT-021 in Healthy Adults","status":"TERMINATED","sponsor":"Arcturus Therapeutics, Inc.","startDate":"2021-01-07","conditions":"Covid19, SARS-CoV Infection, Corona Virus Infection","enrollment":581},{"nctId":"NCT06091189","phase":"EARLY_PHASE1","title":"Internalized Stress in Relation to Alcohol Consumption","status":"TERMINATED","sponsor":"Texas Tech University","startDate":"2024-02-12","conditions":"Stress, Physiological, Ethanol Intoxication, Distress, Emotional","enrollment":165},{"nctId":"NCT04000438","phase":"PHASE2","title":"Effect of Tafoxiparin on Cervical Ripening and Induction of Labor in Term Pregnant Women With an Unripe Cervix","status":"COMPLETED","sponsor":"Dilafor AB","startDate":"2019-06-21","conditions":"Labor Onset and Length Abnormalities","enrollment":365},{"nctId":"NCT05387655","phase":"","title":"Long Term Effects of BCG Vaccination on Infectious and Immune Mediated Diseases","status":"ACTIVE_NOT_RECRUITING","sponsor":"Radboud University Medical Center","startDate":"2022-05-20","conditions":"BCG Vaccination Reaction, Infections, Inflammation","enrollment":4292},{"nctId":"NCT05079230","phase":"PHASE3","title":"Study of Magrolimab Versus Placebo in Combination With Venetoclax and Azacitidine in Participants With Acute Myeloid Leukemia","status":"TERMINATED","sponsor":"Gilead Sciences","startDate":"2022-07-07","conditions":"Acute Myeloid Leukemia","enrollment":378},{"nctId":"NCT04826094","phase":"PHASE1","title":"A Study to Assess the Safety and Immune Response to Env-C DNA and Protein Vaccines in Kenya","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2021-03-15","conditions":"HIV Infections","enrollment":143},{"nctId":"NCT03747341","phase":"PHASE1","title":"Buprenorphine-Fentanyl Interaction Study","status":"COMPLETED","sponsor":"Indivior Inc.","startDate":"2018-03-22","conditions":"Healthy, Opioid Use","enrollment":22},{"nctId":"NCT05633446","phase":"PHASE1, PHASE2","title":"Next Generation T-cell Vaccine Against Coronavirus Disease (COVID-19)","status":"NOT_YET_RECRUITING","sponsor":"Gylden Pharma Ltd","startDate":"2025-09-01","conditions":"Coronavirus, SARS-CoV-2 Infection, COVID-19","enrollment":110},{"nctId":"NCT05914155","phase":"PHASE3","title":"Clinical Study of Rituximab for the Treatment for Idiopathic Membranous Nephropathy with Nephrotic Syndrome","status":"RECRUITING","sponsor":"Shoichi Maruyama MD PhD","startDate":"2023-06-24","conditions":"Glomerulonephritis, Membranous, Nephrotic Syndrome，Idiopathic","enrollment":88},{"nctId":"NCT03307915","phase":"PHASE1","title":"A Study of 2 Different Regimens of Tetravalent Ad26.Mos4.HIV Prime Followed by Boost With Modified Vaccinia Ankara (MVA)-Mosaic OR Ad26.Mos4.HIV Plus a Combination of Mosaic and Clade C gp140 Protein in Human Immunodeficiency Virus (HIV) Type 1 Infected Adults on Suppressive Antiretroviral Treatment","status":"COMPLETED","sponsor":"Janssen Vaccines & Prevention B.V.","startDate":"2018-03-05","conditions":"Human Immunodeficiency Virus","enrollment":25},{"nctId":"NCT02598388","phase":"PHASE2","title":"Safety, Tolerability and Immunogenicity Study of 2-dose Heterologous Regimens for Ebola Vaccines Ad26.ZEBOV/MVA-BN-Filo","status":"COMPLETED","sponsor":"Janssen Vaccines & Prevention B.V.","startDate":"2015-12-10","conditions":"Hemorrhagic Fever, Ebola","enrollment":578},{"nctId":"NCT02919306","phase":"PHASE1, PHASE2","title":"Safety and Efficacy Study of Vaccine Schedule With Ad26.Mos.HIV and MVA-Mosaic in Human Immunodeficiency Virus (HIV)-Infected Adults","status":"COMPLETED","sponsor":"Janssen Vaccines & Prevention B.V.","startDate":"2016-09","conditions":"Human Immunodeficiency Virus","enrollment":27},{"nctId":"NCT03610581","phase":"PHASE1, PHASE2","title":"Safety, Reactogenicity and Immunogenicity of Adenovirus Serotype 26 (Ad26)- and Modified Vaccinia Ankara (MVA)-Vectored Vaccine Components in Otherwise Healthy Women With HPV16 or HPV18 Infection of the Cervix","status":"TERMINATED","sponsor":"Janssen Vaccines & Prevention B.V.","startDate":"2018-09-27","conditions":"Human Papillomavirus Infections","enrollment":9},{"nctId":"NCT05441410","phase":"PHASE1, PHASE2","title":"Comparing Safety and Protective Efficacy of Vaccine Candidate PfSPZ-CVac and MVA ME-TRAP/ ChAd63 ME-TRAP in Adults","status":"NOT_YET_RECRUITING","sponsor":"University Hospital Tuebingen","startDate":"2025-06-01","conditions":"Malaria","enrollment":30},{"nctId":"NCT05178901","phase":"PHASE1","title":"A Phase 1 Study to Evaluate Safety & Immunogenicity of RVSV-Nipah Virus Vaccine Candidate PHV02 in Healthy Adult Subjects","status":"COMPLETED","sponsor":"Public Health Vaccines LLC","startDate":"2022-01-10","conditions":"Nipah Virus Infection","enrollment":60},{"nctId":"NCT03031821","phase":"PHASE3","title":"Metformin in Patients Initiating ADT as Prevention and Intervention of Metabolic Syndrome","status":"TERMINATED","sponsor":"Canadian Urologic Oncology Group","startDate":"2018-07-12","conditions":"Prostate Cancer, Metabolic Syndrome","enrollment":168},{"nctId":"NCT03622879","phase":"NA","title":"Mirror Therapy with Cutaneous Electrical Sensory Stimulation on Lower Limb Motor Functions in Stroke","status":"RECRUITING","sponsor":"The Hong Kong Polytechnic University","startDate":"2018-07-02","conditions":"Stroke","enrollment":100},{"nctId":"NCT05389930","phase":"PHASE2","title":"Cannabis' Impact on Alcohol Consumption","status":"RECRUITING","sponsor":"Brown University","startDate":"2023-03-16","conditions":"Alcohol Drinking, Cannabis Use, Cannabis","enrollment":350},{"nctId":"NCT03989336","phase":"PHASE2","title":"A Study of the Pan-immunotherapy in Patients With Relapsed/Refractory Ovarian Cancer","status":"COMPLETED","sponsor":"Chinese PLA General Hospital","startDate":"2020-12-23","conditions":"Ovarian Cancer","enrollment":84},{"nctId":"NCT04707391","phase":"PHASE3","title":"Immunogenicity and Safety Study of GSK's MenABCWY Vaccine in Healthy Adolescents and Adults Previously Primed With MenACWY Vaccine","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2021-01-25","conditions":"Meningitis, Meningococcal","enrollment":1250},{"nctId":"NCT04313881","phase":"PHASE3","title":"Magrolimab + Azacitidine Versus Azacitidine + Placebo in Untreated Participants With Myelodysplastic Syndrome (MDS)","status":"TERMINATED","sponsor":"Gilead Sciences","startDate":"2020-09-09","conditions":"Myelodysplastic Syndromes","enrollment":539},{"nctId":"NCT03911076","phase":"PHASE2","title":"Phase II Study of Treatment for HPV16+ ASC-US, ASC-H and LSIL","status":"TERMINATED","sponsor":"PapiVax Biotech, Inc.","startDate":"2019-05-22","conditions":"ASC-US, ASC-H, LSIL","enrollment":16},{"nctId":"NCT06022224","phase":"PHASE2, PHASE3","title":"A 2nd Generation E1/E2B/E3-Deleted Adenoviral COVID-19 Vaccine: The TCELL VACCINE TRIAL","status":"TERMINATED","sponsor":"ImmunityBio, Inc.","startDate":"2020-12-09","conditions":"COVID-19","enrollment":35},{"nctId":"NCT03817125","phase":"PHASE1","title":"Melanoma Checkpoint and Gut Microbiome Alteration With Microbiome Intervention","status":"COMPLETED","sponsor":"Parker Institute for Cancer Immunotherapy","startDate":"2019-01-28","conditions":"Metastatic Melanoma","enrollment":14},{"nctId":"NCT06419686","phase":"PHASE1","title":"The Glucagonotropic Effects of Glucose-dependent Insulinotropic Polypeptide and Alanine in Healthy Individuals","status":"RECRUITING","sponsor":"University Hospital, Gentofte, Copenhagen","startDate":"2024-01-01","conditions":"Effect of iv Administration of GIP and Alanine","enrollment":10},{"nctId":"NCT02963909","phase":"PHASE1","title":"A Phase 1, First-in-human, Double-blinded, Randomized, Placebo-controlled Trial of a Zika Virus Purified Inactivated Vaccine (ZPIV) With Alum Adjuvant in Healthy Flavivirus-naive and Flavivirus-Primed Subjects.","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2016-11-01","conditions":"Zika Virus Infection","enrollment":75},{"nctId":"NCT04549662","phase":"NA","title":"The HepatoPancreaticoBiliary Resection Arginine Immunomodulation (PRIMe) Trial","status":"COMPLETED","sponsor":"Sunnybrook Health Sciences Centre","startDate":"2021-06-16","conditions":"Hepatopancreaticobiliary (HPB) Malignancy, Surgery","enrollment":45},{"nctId":"NCT06252467","phase":"NA","title":"Photobiomodulation Therapy on Performance in Successive Cycling Tests","status":"COMPLETED","sponsor":"Marco Aurélio Vaz, PhD","startDate":"2014-07-14","conditions":"Photobiomodulation Therapy, Cyclists, Performance","enrollment":16},{"nctId":"NCT04990466","phase":"PHASE2, PHASE3","title":"Phase 2b/3 Trial of VSV-ΔG SARS-CoV-2 Vaccine (BRILIFE) Against Approved Comparator Vaccine.","status":"WITHDRAWN","sponsor":"NeuroRx, Inc.","startDate":"2021-09-30","conditions":"COVID-19","enrollment":""},{"nctId":"NCT06213506","phase":"PHASE2","title":"A Study on the Safety, Reactogenicity, and Immune Response to the GVGH iNTS-GMMA Vaccine Against Invasive Nontyphoidal Salmonella in Adults, Children, and Infants","status":"RECRUITING","sponsor":"GlaxoSmithKline","startDate":"2024-01-15","conditions":"Salmonella Infections","enrollment":516},{"nctId":"NCT04354259","phase":"PHASE2","title":"Interferon Lambda for Immediate Antiviral Therapy at Diagnosis in COVID-19","status":"COMPLETED","sponsor":"University Health Network, Toronto","startDate":"2020-05-13","conditions":"Sars-CoV2, Covid-19","enrollment":157},{"nctId":"NCT04992832","phase":"PHASE1, PHASE2","title":"Multi-intravenous Infusion of Umbilical Cord Mesenchymal Stem Cells in Heart Failure With Reduced Ejection Fraction（PRIME-HFrEF Study）","status":"COMPLETED","sponsor":"Shanghai East Hospital","startDate":"2021-07-28","conditions":"Heart Failure, Systolic","enrollment":40},{"nctId":"NCT04608305","phase":"PHASE1, PHASE2","title":"Evaluate the Safety, Immunogenicity and Potential Efficacy of an rVSV-SARS-CoV-2-S Vaccine","status":"COMPLETED","sponsor":"Israel Institute for Biological Research (IIBR)","startDate":"2020-10-28","conditions":"Covid19","enrollment":843},{"nctId":"NCT06116942","phase":"NA","title":"Magnetic Brain Stimulation and Computer-based Motor Training for Rehabilitation After Stroke","status":"RECRUITING","sponsor":"Max Planck Institute for Human Cognitive and Brain Sciences","startDate":"2023-11-08","conditions":"Chronic Stroke","enrollment":24},{"nctId":"NCT04742842","phase":"PHASE1","title":"The Safety and Immunogenicity of a DNA-based Vaccine (COVIGEN) in Healthy Volunteers","status":"COMPLETED","sponsor":"University of Sydney","startDate":"2021-06-21","conditions":"SARS-CoV2 COVID-19","enrollment":68},{"nctId":"NCT06049706","phase":"NA","title":"Priming in Repetitive Transcranial Magnetic Stimulation in the Treatment of Obsessive Compulsive Disorder","status":"UNKNOWN","sponsor":"Suellen Andrade","startDate":"2022-05-17","conditions":"Obsessive-Compulsive Disorder","enrollment":32},{"nctId":"NCT05579964","phase":"PHASE2, PHASE3","title":"The Role of Dexmedetomidine as Myocardial Protector in Pediatric Cardiac Surgery Total Correction of Tetralogy of Fallot","status":"COMPLETED","sponsor":"National Cardiovascular Center Harapan Kita Hospital Indonesia","startDate":"2022-10-10","conditions":"Congenital Heart Disease in Children, Cardiopulmonary Bypass, Tetralogy of Fallot","enrollment":66},{"nctId":"NCT05422326","phase":"PHASE2","title":"A Study to Evaluate Safety and Immunogenicity of One or Two Booster Vaccinations With H5N6 Influenza Vaccine in Adults Primed With H5N1 Influenza Vaccine or Unprimed","status":"COMPLETED","sponsor":"Seqirus","startDate":"2022-07-18","conditions":"Influenza, Human, Influenza in Birds, Respiratory Tract Infections","enrollment":260},{"nctId":"NCT03942406","phase":"PHASE2","title":"Study of BPZE1 Intranasal Pertussis Vaccine (Administered Via VaxINator(TM)), Prime + Boost, in Healthy Adults","status":"COMPLETED","sponsor":"ILiAD Biotechnologies","startDate":"2019-06-15","conditions":"Pertussis, Whooping Cough","enrollment":300},{"nctId":"NCT04446052","phase":"PHASE3","title":"Phase III rhu_GM-CSF + 3 Induction Regimens in Adults With Acute Non-Lymphocytic Leukemia","status":"COMPLETED","sponsor":"Eastern Cooperative Oncology Group","startDate":"1993-05-21","conditions":"Adult Patients (Over 55) With Acute Non-Lymphocytic Leukemia","enrollment":362},{"nctId":"NCT04672720","phase":"NA","title":"L-carnitine and COH in PCOS Women Undergoing IVF/ICSI Cycles","status":"COMPLETED","sponsor":"Royan Institute","startDate":"2020-03-01","conditions":"Polycystic Ovary Syndrome","enrollment":110},{"nctId":"NCT05184699","phase":"NA","title":"The Effect of Dietary Intervention on Endothelial Glycocalyx in Psoriasis","status":"UNKNOWN","sponsor":"University of Athens","startDate":"2022-11-01","conditions":"Psoriasis","enrollment":60},{"nctId":"NCT03775382","phase":"NA","title":"Mechanisms of Impaired Brain Blood Flow With Aging","status":"COMPLETED","sponsor":"University of Delaware","startDate":"2017-10-30","conditions":"Aging","enrollment":34},{"nctId":"NCT02296541","phase":"PHASE1","title":"Evaluating the Safety and Immune Response to Three Different DNA HIV Vaccines Administered With a MVA-CMDR Boost Vaccine in Healthy, HIV-Uninfected Adults","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2014-12","conditions":"HIV Infections","enrollment":105},{"nctId":"NCT04998240","phase":"PHASE2","title":"Mix and Match Heterologous Prime-Boost Study Using Approved COVID-19 Vaccines","status":"UNKNOWN","sponsor":"International Vaccine Institute","startDate":"2021-12-29","conditions":"Covid19","enrollment":360},{"nctId":"NCT04324268","phase":"PHASE1","title":"A Study to Evaluate Safety, Tolerability, and Bioavailability of Subcutaneous Lirentelimab (AK002) in Adult Healthy Volunteers","status":"COMPLETED","sponsor":"Allakos Inc.","startDate":"2020-03-23","conditions":"Study Conducted in Healthy Volunteers","enrollment":66},{"nctId":"NCT03060629","phase":"PHASE2","title":"A Study to Assess the Efficacy of a Heterologous Prime/Boost Vaccine Regimen of Ad26.Mos4.HIV and Aluminum Phosphate-Adjuvanted Clade C gp140 in Preventing Human Immunodeficiency Virus (HIV) -1 Infection in Women in Sub-Saharan Africa","status":"TERMINATED","sponsor":"Janssen Vaccines & Prevention B.V.","startDate":"2017-11-03","conditions":"HIV-1","enrollment":2636},{"nctId":"NCT05592561","phase":"NA","title":"Impact of Supplements on Stress Markers","status":"COMPLETED","sponsor":"Texas State University","startDate":"2022-01-25","conditions":"Physiological Stress","enrollment":109},{"nctId":"NCT03008122","phase":"PHASE1","title":"Phase I, Randomized, Double-blinded, Placebo-Controlled Dose De-escalation Study to Evaluate Safety and Immunogenicity of Alum Adjuvanted Zika Virus Purified Inactivated Vaccine (ZPIV) in Adults in a Flavivirus Endemic Area","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2017-03-21","conditions":"Zika Virus Infection","enrollment":91},{"nctId":"NCT04394689","phase":"PHASE1, PHASE2","title":"Measles and Rubella Vaccine Microneedle Patch Phase 1-2 Age De-escalation Trial","status":"COMPLETED","sponsor":"Micron Biomedical, Inc","startDate":"2021-05-19","conditions":"Measles, Rubella, Vaccination","enrollment":281},{"nctId":"NCT02853604","phase":"PHASE3","title":"Study of ADXS11-001 in Participants With High Risk Locally Advanced Cervical Cancer","status":"TERMINATED","sponsor":"Advaxis, Inc.","startDate":"2015-12-15","conditions":"High Risk Cervical Cancer, Advanced Cervical Cancer","enrollment":110},{"nctId":"NCT04334980","phase":"PHASE1","title":"Evaluating the Safety, Tolerability and Immunogenicity of bacTRL-Spike Vaccine for Prevention of COVID-19","status":"COMPLETED","sponsor":"Symvivo Corporation","startDate":"2020-11-02","conditions":"COVID-19","enrollment":24},{"nctId":"NCT03873727","phase":"PHASE2","title":"Revaccination With PPS23 Boosted or Not by PCV13 in Splenectomised Patients.","status":"UNKNOWN","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2019-08-27","conditions":"Splenectomised Patients","enrollment":39},{"nctId":"NCT05300802","phase":"PHASE2, PHASE3","title":"The Role of Dexmedetomidine As Myocardial Protection In Pediatric Cyanotic Congenital Heart Disease Undergoing Open Cardiac Surgery Using Cardiopulmonary Bypass Machine: A Preliminary Study","status":"COMPLETED","sponsor":"National Cardiovascular Center Harapan Kita Hospital Indonesia","startDate":"2021-12-16","conditions":"Congenital Heart Disease in Children, Cardiopulmonary Bypass","enrollment":15},{"nctId":"NCT00820846","phase":"PHASE2","title":"Safety of and Immune Response to a Prime-Boost Vaccine Regimen in HIV-Uninfected Vaccine-Naive Adults","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2009-01","conditions":"HIV Infections","enrollment":299},{"nctId":"NCT03370510","phase":"PHASE2","title":"Translating Neuroprediction Into Precision Medicine Via Brain Priming","status":"TERMINATED","sponsor":"Yale University","startDate":"2018-12-07","conditions":"Autism Spectrum Disorder","enrollment":5},{"nctId":"NCT02852005","phase":"PHASE1","title":"Evaluating the Immunogenicity of the AIDSVAX B/E Vaccine and the MVA/HIV62B Vaccine in Healthy, HIV-1-Uninfected Adults Who Previously Received MVA/HIV62B in DNA/MVA or MVA/MVA Regimens in HVTN 205","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2017-01","conditions":"HIV Infections","enrollment":27},{"nctId":"NCT03788083","phase":"PHASE1","title":"Intratumoral TriMix Injections in Early Breast Cancer Patients","status":"UNKNOWN","sponsor":"Universitair Ziekenhuis Brussel","startDate":"2018-11-12","conditions":"Breast Cancer Female, Early-stage Breast Cancer","enrollment":36},{"nctId":"NCT03409276","phase":"PHASE1","title":"Evaluating the Safety and Immunogenicity of Env (A,B,C,A/E)/Gag (C) DNA and gp120 (A,B,C,A/E) Protein/GLA-SE HIV Vaccines, Given Individually or Co-administered, in Healthy, HIV-1-Uninfected Adults","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2018-03-16","conditions":"HIV Infections","enrollment":60},{"nctId":"NCT04833101","phase":"PHASE4","title":"Study on Heterologous Prime-boost of Recombinant COVID-19 Vaccine (Ad5 Vector) and RBD-based Protein Subunit Vaccine","status":"COMPLETED","sponsor":"Jiangsu Province Centers for Disease Control and Prevention","startDate":"2021-04-07","conditions":"COVID-19","enrollment":120},{"nctId":"NCT04967430","phase":"PHASE3","title":"TOGETHER - Toronto: Trial to Evaluate the Effect of Peginterferon Lambda for the Treatment of COVID-19","status":"UNKNOWN","sponsor":"University Health Network, Toronto","startDate":"2021-08-27","conditions":"Sars-CoV2, Covid19","enrollment":763},{"nctId":"NCT05248373","phase":"PHASE1, PHASE2","title":"Safety, Tolerability and Immunogenicity of Gam-COVID-Vac Vaccine in a Nasal Spray","status":"UNKNOWN","sponsor":"Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation","startDate":"2022-03-08","conditions":"COVID-19, SARS-CoV-2 Acute Respiratory Disease","enrollment":400},{"nctId":"NCT02564523","phase":"PHASE2","title":"Safety, Tolerability and Immunogenicity Study of 3 Prime-boost Regimens for Ebola Vaccines Ad26.ZEBOV/MVA-BN-Filo in Healthy Adults, Children and Human Immunodeficiency Virus Positive (HIV+) Adults","status":"COMPLETED","sponsor":"Janssen Vaccines & Prevention B.V.","startDate":"2015-11-06","conditions":"Hemorrhagic Fever, Ebola","enrollment":1075}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Placebo","rocuronium-priming"],"phase":"marketed","status":"active","brandName":"Placebo priming","genericName":"Placebo priming","companyName":"Yun-Fan Liaw","companyId":"yun-fan-liaw","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Placebo priming leverages expectancy and conditioning effects to enhance the body's natural healing response through psychological and physiological mechanisms. Used for Chronic pain conditions, Depression and anxiety disorders, Irritable bowel syndrome.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}